WO2001042445A3 - USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS - Google Patents

USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS Download PDF

Info

Publication number
WO2001042445A3
WO2001042445A3 PCT/US2000/033293 US0033293W WO0142445A3 WO 2001042445 A3 WO2001042445 A3 WO 2001042445A3 US 0033293 W US0033293 W US 0033293W WO 0142445 A3 WO0142445 A3 WO 0142445A3
Authority
WO
WIPO (PCT)
Prior art keywords
piv
chimeric
genome
antigenome
pivs
Prior art date
Application number
PCT/US2000/033293
Other languages
French (fr)
Other versions
WO2001042445A2 (en
Inventor
Brian R Murphy
Peter L Collins
Alexander C Schmidt
Anna P Durbin
Mario H Skiadopoulos
Tao Tao
Original Assignee
Us Health
Brian R Murphy
Peter L Collins
Alexander C Schmidt
Anna P Durbin
Mario H Skiadopoulos
Tao Tao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/459,062 external-priority patent/US7250171B1/en
Priority claimed from US09/458,813 external-priority patent/US7314631B1/en
Application filed by Us Health, Brian R Murphy, Peter L Collins, Alexander C Schmidt, Anna P Durbin, Mario H Skiadopoulos, Tao Tao filed Critical Us Health
Priority to CA002362685A priority Critical patent/CA2362685A1/en
Priority to AU20731/01A priority patent/AU785148B2/en
Priority to IL14483100A priority patent/IL144831A0/en
Priority to MXPA01008108A priority patent/MXPA01008108A/en
Priority to JP2001544321A priority patent/JP4795597B2/en
Priority to EP00984052A priority patent/EP1179054A2/en
Publication of WO2001042445A2 publication Critical patent/WO2001042445A2/en
Publication of WO2001042445A3 publication Critical patent/WO2001042445A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human, bovine, or human-bovine chimeric, PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.
PCT/US2000/033293 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS WO2001042445A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002362685A CA2362685A1 (en) 1999-12-10 2000-12-08 Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens
AU20731/01A AU785148B2 (en) 1999-12-10 2000-12-08 Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
IL14483100A IL144831A0 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
MXPA01008108A MXPA01008108A (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS.
JP2001544321A JP4795597B2 (en) 1999-12-10 2000-12-08 Use of recombinant PIV as a vector to protect against infections and diseases caused by parainfluenza virus (PIV) and human pathogens
EP00984052A EP1179054A2 (en) 1999-12-10 2000-12-08 Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17019599P 1999-12-10 1999-12-10
US09/459,062 US7250171B1 (en) 1997-05-23 1999-12-10 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US09/459,062 1999-12-10
US60/170,195 1999-12-10
US09/458,813 US7314631B1 (en) 1997-05-23 1999-12-10 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US09/458,813 1999-12-10

Publications (2)

Publication Number Publication Date
WO2001042445A2 WO2001042445A2 (en) 2001-06-14
WO2001042445A3 true WO2001042445A3 (en) 2001-11-29

Family

ID=27389780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033293 WO2001042445A2 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Country Status (8)

Country Link
EP (1) EP1179054A2 (en)
JP (1) JP4795597B2 (en)
CN (2) CN102766605A (en)
AU (1) AU785148B2 (en)
CA (1) CA2362685A1 (en)
IL (1) IL144831A0 (en)
MX (1) MXPA01008108A (en)
WO (1) WO2001042445A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
SG149684A1 (en) 2001-01-19 2009-02-27 Vironovative Bv A virus causing respiratory tract illness in susceptible animals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
ATE509097T1 (en) 2001-11-21 2011-05-15 Us Health OBTAINING RECOMBINANT HUMAN PARAINFLUENZAVIRUS TYPE 1 (HPIVI) FROM CDNA
EP1576090A4 (en) 2002-02-21 2008-07-16 Medimmune Vaccines Inc Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
WO2004003511A2 (en) 2002-07-01 2004-01-08 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
WO2004027037A2 (en) 2002-09-18 2004-04-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
AU2004262624B2 (en) 2003-02-28 2009-11-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
AU2004250129A1 (en) 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded RNA viruses from cDNA
DE102005006388A1 (en) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replication-deficient RNA viruses as vaccines
WO2006122224A1 (en) 2005-05-11 2006-11-16 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in pseudomonas aeruginosa
AU2006243923B2 (en) 2005-05-11 2011-09-22 Wayne State University Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance
JP4905649B2 (en) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 Fish vaccine, method for producing the same, and method for preventing fish infection
JP4892296B2 (en) 2006-08-24 2012-03-07 川崎製薬株式会社 Vaccines for fish edovagerosis and streptococcal disease
US8362203B2 (en) 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
WO2013112690A1 (en) 2012-01-24 2013-08-01 Universtiy Of Georgia Research Foundation, Inc. Piv5 as oncolytic agent
CN103773803A (en) * 2014-01-23 2014-05-07 中国农业科学院特产研究所 Recombined cattle parainfluenza carrier for expressing protein VP1 of porcine O type foot-and-mouth disease virus
CN110996998A (en) * 2017-05-29 2020-04-10 美利坚合众国- 由健康及人类服务部部长代表 Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and uses thereof
AU2019295497A1 (en) * 2018-06-27 2020-11-26 Medicago Inc. Influenza virus hemagglutinin mutants
EP3844758A1 (en) * 2018-08-28 2021-07-07 Koninklijke Philips N.V. Method for assessing genome alignment basis
CN113462656B (en) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 Human three-type parainfluenza virus cold-adaptation temperature-sensitive strain and application thereof
CN113999292B (en) * 2021-10-27 2023-05-26 中国农业大学 Polypeptide inhibitors targeting respiratory viruses
WO2023227758A1 (en) 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053078A1 (en) * 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
WO2001004320A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053078A1 (en) * 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
WO2001004320A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENG R ET AL: "Functional chimeric HN glycoproteins derived from Newcastle disease virus and human parainfluenza virus-3.", ARCHIVES OF VIROLOGY SUPPLEMENT, no. 13, 1997, pages 115 - 130, XP001005401, ISSN: 0939-1983 *
SKIADOPOULOS MARIO H ET AL: "Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.", VACCINE, vol. 18, no. 5-6, 14 October 1999 (1999-10-14), pages 503 - 510, XP001000985, ISSN: 0264-410X *
TAO T ET AL: "A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.", VACCINE, vol. 17, no. 9-10, 5 March 1999 (1999-03-05), pages 1100 - 1108, XP004158231, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2001042445A2 (en) 2001-06-14
AU2073101A (en) 2001-06-18
CA2362685A1 (en) 2001-06-14
MXPA01008108A (en) 2004-11-12
AU785148B2 (en) 2006-10-05
EP1179054A2 (en) 2002-02-13
IL144831A0 (en) 2002-06-30
JP2003516148A (en) 2003-05-13
CN1347453A (en) 2002-05-01
CN102766605A (en) 2012-11-07
JP4795597B2 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
ATE419369T1 (en) CHIMERIC HUMAN-CAVINE RESPIRATORY SYNCYTIAL VIRUS VACCINES
WO2003072719A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2004027037A3 (en) RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
WO2004096993A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2006044923A3 (en) Yeast-based therapeutic for chronic hepatitis c infection
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
WO2003043587A3 (en) Recovery of recombinant human parainfluenza virus type 1 (hpiv1) from cdna
PL398576A1 (en) Vaccine preparations, pharmaceutical preparations, attenuated influenza virus, vaccination methods, methods for the prevention of an infectious disease, methods of treatment or prevention of cancers, vaccine compositions and pharmaceutical compositions
MXPA01013302A (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines.
WO2005014626A3 (en) Recombinant human metapneumovirus and its use
WO2010079505A3 (en) Combined measles-human papilloma vaccine
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
WO2022140364A3 (en) African swine fever (asf) virus vaccines
MXPA02001223A (en) Proteins derived from white spot syndrome virus and uses thereof.
MXPA05005203A (en) Vaccine against hcv.
WO2006073496A3 (en) Recombinant aav based vaccine methods
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
DE60136811D1 (en) RESPIRATORY SYNZYTIALVIRUS VACCINES EXPRESSING PROTECTIVE ANTIGENS FROM PROMOTOR PROXIMAL GENES
DK177298B1 (en) Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines
WO2000012684A3 (en) Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (hpiv-2) and vaccines based on such virus
BR0105530A (en) Parainfluenza virus, methods for stimulating a patient's immune system to induce protection against parainfluenza virus and for producing a particle of parainfluenza virus, a sequential immunization method for stimulating a patient's immune system to induce protection against multiple pathogens, immunogenic composition to evoke an immune response against parainfluenza virus, isolated polynucleotide and expression vector

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00805939.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2362685

Country of ref document: CA

Ref document number: 2362685

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144831

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 544321

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/008108

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20731/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000984052

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000984052

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642